Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Rigosertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Rigosertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Rilotumumab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Rilotumumab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Rilvegostomig |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Rilvegostomig
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Robatumumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Robatumumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Rovalpituzumab (Ref) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Rovalpituzumab (Ref)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Sabatolimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Sabatolimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Sacituzumab Tirumotecan |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Sacituzumab Tirumotecan
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Seliciclib (CDK Inhibitor) |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Seliciclib (CDK Inhibitor)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
Selumetinib Sulfate |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Selumetinib Sulfate
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Seribantumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Seribantumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Setogepram |
SARM (Selective Androgen Receptor Modulator) | Solid Tumour | ||
|
Molecule
Setogepram
Therapeutic Category
Supportive Care (Investigational Cachexia)
Oncology Type
Solid Tumour
Drug Class / Mechanism
SARM (Selective Androgen Receptor Modulator) |
||||
Sevabertinib |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Sevabertinib
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
RigosertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
RilotumumabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
RilvegostomigImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
RobatumumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Rovalpituzumab (Ref)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
SabatolimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
Sacituzumab TirumotecanTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Seliciclib (CDK Inhibitor)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
Selumetinib SulfateTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
SeribantumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
SetogepramSupportive Care (Investigational Cachexia) |
|
|
Therapeutic Category
Supportive Care (Investigational Cachexia)
Oncology Type
Solid Tumour
Drug Class / Mechanism
SARM (Selective Androgen Receptor Modulator) |
|
SevabertinibTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|